BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-132@catalystbrief.girapphe.com
DTSTAMP:20261117T181601Z
LAST-MODIFIED:20261117T181601Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Exelixis — XL092 [Dec 2026]
DESCRIPTION:Phase 3 primary completion: Study of XL092 + Nivolumab vs Sunit
 inib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Car
 cinoma.\nSource: https://clinicaltrials.gov/study/NCT05678673\nhttps://cat
 alystbrief.girapphe.com/e/132?lang=en\nNot investment advice. Dates may ch
 ange.
URL:https://catalystbrief.girapphe.com/e/132?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
